Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom

Hepatitis C in patients with β-thalassemia major. A single-centre experience

(2013) Christos Triantos et al.   ANNALS OF HEMATOLOGY

Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program

(2013) Rosarin Sruamsiri et al.   BMC HEALTH SERVICES RESEARCH

Combined Chelation Therapy with Deferoxamine and Deferiprone in β-Thalassemia Major: Compliance and Opinions of Young Thalassemic Patients

(2013) Emmanuel S. Hatzipantelis et al.   HEMOGLOBIN

Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective

(2013) Anthony Bentley et al.   PHARMACOECONOMICS

Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME)

(2013) Elliott Vichinsky et al.   TRANSFUSION

Common Complications in Beta-Thalassemia Patients.

(2013) Ayhan Yaman   UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi

Lifetime Cost-Utility Analyses of Deferasirox in Beta-Thalassaemia Patients with Chronic Iron Overload

(2012) Jonathan Karnon et al.   CLINICAL DRUG INVESTIGATION

Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study

(2011) G. Derchi et al.   European Journal of Echocardiography

Catalogue of EQ-5D Scores for the United Kingdom

(2011) Patrick W. Sullivan et al.   MEDICAL DECISION MAKING

A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand

(2010) Pattara Leelahavarong et al.   BMC HEALTH SERVICES RESEARCH

The influence of treatment in specialized centers on survival of patients with thalassemia major

(2009) Gian Luca Forni et al.   AMERICAN JOURNAL OF HEMATOLOGY

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies

(2009) Aurelio Maggio et al.   BLOOD CELLS MOLECULES AND DISEASES

Long-term sequential deferiprone-deferoxamineversusdeferiprone alone for thalassaemia major patients: a randomized clinical trial

(2009) Aurelio Maggio et al.   BRITISH JOURNAL OF HAEMATOLOGY

Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results

(2009) Isabelle Thuret et al.   Hematology

Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload

(2008) Krista A. Payne et al.   ADVANCES IN THERAPY